We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE provided more detail into how the process will work, with the early value assessments providing...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe HTA initially recommended Tremfya as a treatment option for adults with active psoriatic arthrit...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE have been clear that this framework should not be interpreted as minimum standards for real-wor...
Read moreThe aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.
Read moreThe subscription-style payment model for antibiotics announced by NICE in April 2022 will be capped ...
Read moreThe Access Consortium is made up of regulatory authorities including the UK, Australia, Canada, Sing...
Read moreDurvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...
Read more